Bhumsuk Keam
YOU?
Author Swipe
Neoadjuvant Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy in Thymic Epithelial Tumors: A Propensity Score-Matched Analysis Open
Background: Neoadjuvant chemotherapy is generally recommended for locally advanced, potentially resectable thymic epithelial tumors. However, neoadjuvant chemoradiotherapy has been proposed as an alternative approach, potentially achieving…
Association between multidrug-resistant organism status and quality of end-of-life care in patients with advanced cancer referred to palliative care: a retrospective cohort study with nationwide data linkage Open
MDRO status could be associated with lower quality of end-of-life care, including reduced access to community-based hospice and more aggressive interventions, in patients with advanced cancer referred for PC. These findings underscore the …
View article: Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study Open
Overexpression of EGFR and MET occurs in a high proportion of recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Amivantamab, an EGFR-MET bispecific antibody with immune-cell directing activity, is approved in…
View article: Clinical Characteristics Associated with High [68Ga]Ga-PSMA-11 Uptake and Preliminary Therapeutic Outcomes in Patients with Metastatic Adenoid Cystic Carcinoma
Clinical Characteristics Associated with High [68Ga]Ga-PSMA-11 Uptake and Preliminary Therapeutic Outcomes in Patients with Metastatic Adenoid Cystic Carcinoma Open
Purpose Adenoid cystic carcinoma (ACC) is a rare cancer that arises from the salivary glands. Recent studies have shown that prostate-specific membrane antigen (PSMA) expression is high in ACC. We conducted a prospective study to evaluate …
View article: A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24)
A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24) Open
Durvalumab combined with doxorubicin and ifosfamide suggested clinical activity in recurrent and/or metastatic PSC. Larger studies are warranted to confirm benefits and refine treatment strategies.
View article: Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer
Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer Open
Importance Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood. Objective To describe the patterns of broad-spectrum antibiotic u…
View article: Preferential Sensitivity of the <i>EGFR</i> L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Preferential Sensitivity of the <i>EGFR</i> L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Open
The EGFR L858M/L861R mutation drives strong oncogenic signaling and exhibits preferential sensitivity to second-generation EGFR TKIs. These findings underscore the importance of accurate molecular diagnosis for guiding effective, personali…
The Small Molecule Inhibitor of the Wnt–β‐Catenin Pathway, <span>CWP232291</span> , Inhibits Tumor Growth in Preclinical Models of Salivary Gland Adenoid Cystic Carcinoma Open
Background Salivary gland adenoid cystic carcinoma (ACC) is a rare and challenging form of head and neck cancer, particularly difficult to treat once it progresses to recurrent or metastatic disease. In this study, we evaluate the cytotoxi…
View article: ED Visits Among Patients With Advanced Cancer Referred to Outpatient Palliative Care
ED Visits Among Patients With Advanced Cancer Referred to Outpatient Palliative Care Open
Importance Emergency department (ED) visits among patients with cancer reflect unmet needs and may indicate poor care quality. Outpatient palliative care interventions may help minimize unnecessary ED visits and improve care alignment with…
View article: Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Supplementary material
View article: Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma
Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma Open
Increased infiltration of both iTIL and sTIL is associated with longer PFS and OS. Additionally, an inflamed IP is associated with longer PFS. Thus, TIL density and IP may be promising predictive biomarkers for pembrolizumab in patients wi…
View article: Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose:Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mona…
View article: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mon…
View article: Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial Open
Purpose The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAα (phosphatidylinositol-4,5-bisphosphate 3-kina…
View article: Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications
Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications Open
We identified two intimal sarcoma molecular subtypes. Compared with CNV-H, MSI-H-like is enriched in pathways associated with tumor immune responses and TILs. Further efforts and clinical trials to better define these molecular subtypes ar…
View article: Supplementary Table S9 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Table S9 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
The most up- or downregulated gene sets in tumor cells between IF_PDL1H and ID_PDL1H
View article: Data from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Data from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
The expression of PD-L1 on tumor cells (TC) is used as an immunotherapy biomarker in lung cancer, but heterogeneous intratumoral expression is often observed. To better understand heterogeneity in the lung cancer tumor microenvironment, we…
View article: Supplementary Tables S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Tables S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
Characteristics of patients with lung cancer treated with immune checkpoint inhibitor (immunohistochemistry cohort)
View article: Supplementary Figure S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Figure S3 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
The characteristics of immune cells according to tumor PD-L1 expression in immune deficient tumor microenvironment.
View article: Supplementary Table S7 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Table S7 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
The most up- or downregulated gene sets in immune cells between IF_PDL1H and IF_PDL1L
View article: Supplementary Figure S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Figure S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
Survival analysis according to subtype of NSCLC in ICI cohort
View article: Supplementary Tables S4 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Tables S4 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
List of protein molecules identified using nCounter analysis
View article: Supplementary Figure S2 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Figure S2 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
Principal Component Analysis (PCA) and the distribution of tumor PD-L1 expression in total or per group using DSP analysis.
View article: Supplementary Table 8S from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Table 8S from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
The most up- or downregulated gene sets in immune cells between ID_PDL1H and ID_PDL1L
View article: Supplementary Table S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Table S6 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
Publicly available data source and analysis
View article: Supplementary Table S5 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression
Supplementary Table S5 from Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression Open
List of genes in various T cell status signatures